These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 26927204

  • 1. Treatment Patterns and Health Care Costs for Age-Related Macular Degeneration in Japan: An Analysis of National Insurance Claims Data.
    Kume A, Ohshiro T, Sakurada Y, Kikushima W, Yoneyama S, Kashiwagi K.
    Ophthalmology; 2016 Jun; 123(6):1263-8. PubMed ID: 26927204
    [Abstract] [Full Text] [Related]

  • 2. Incidence and Clinical Practice of Exudative Age-related Macular Degeneration: A Nationwide Population-Based Cohort Study.
    Kido A, Miyake M, Tamura H, Hiragi S, Kimura T, Yoshida S, Takeuchi M, Ohtera S, Takahashi A, Ooto S, Kawakami K, Kuroda T, Tsujikawa A.
    Ophthalmol Sci; 2022 Jun; 2(2):100125. PubMed ID: 36249688
    [Abstract] [Full Text] [Related]

  • 3. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
    Coleman AL, Yu F.
    Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
    [Abstract] [Full Text] [Related]

  • 4. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I.
    Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
    [Abstract] [Full Text] [Related]

  • 5. Incremental economic burden associated with exudative age-related macular degeneration: a population-based study.
    Kim S, Park SJ, Byun SJ, Park KH, Suh HS.
    BMC Health Serv Res; 2019 Nov 12; 19(1):828. PubMed ID: 31718629
    [Abstract] [Full Text] [Related]

  • 6. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ, Bell CM, Paterson JM, Bronskill SE, Moineddin R, Whitehead M, Gill SS.
    Ophthalmology; 2012 Aug 12; 119(8):1604-8. PubMed ID: 22717458
    [Abstract] [Full Text] [Related]

  • 7. Economic implications of current age-related macular degeneration treatments.
    Smiddy WE.
    Ophthalmology; 2009 Mar 12; 116(3):481-7. PubMed ID: 19157562
    [Abstract] [Full Text] [Related]

  • 8. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries.
    Curtis LH, Hammill BG, Qualls LG, DiMartino LD, Wang F, Schulman KA, Cousins SW.
    Am J Ophthalmol; 2012 Jun 12; 153(6):1116-24.e1. PubMed ID: 22321802
    [Abstract] [Full Text] [Related]

  • 9. Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study.
    French DD, Margo CE.
    Retina; 2011 Jun 12; 31(6):1036-42. PubMed ID: 21836410
    [Abstract] [Full Text] [Related]

  • 10. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
    Erie JC, Barkmeier AJ, Hodge DO, Mahr MA.
    Ophthalmology; 2016 Jun 12; 123(6):1257-62. PubMed ID: 26976701
    [Abstract] [Full Text] [Related]

  • 11. Prevalence and Incidence of Exudative Age-Related Macular Degeneration in South Korea: A Nationwide Population-Based Study.
    Park SJ, Kwon KE, Choi NK, Park KH, Woo SJ.
    Ophthalmology; 2015 Oct 12; 122(10):2063-70.e1. PubMed ID: 26208437
    [Abstract] [Full Text] [Related]

  • 12. [Age-related macular degeneration: a socioeconomic time bomb in our aging society].
    Schrader WF.
    Ophthalmologe; 2006 Sep 12; 103(9):742-8. PubMed ID: 16924447
    [Abstract] [Full Text] [Related]

  • 13. [Age-related macular degeneration--new options for therapy?].
    Bornfeld N.
    Klin Monbl Augenheilkd; 2005 May 12; 222(5):379-80. PubMed ID: 15912453
    [No Abstract] [Full Text] [Related]

  • 14. Relative cost of a line of vision in age-related macular degeneration.
    Smiddy WE.
    Ophthalmology; 2007 May 12; 114(5):847-54. PubMed ID: 17306878
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Guidance for the treatment of neovascular age-related macular degeneration (AMD)].
    Karska-Basta I, Kubicka-Trzaska A, Oleksy P, Romanowska-Dixon B.
    Przegl Lek; 2009 May 12; 66(11):972-5. PubMed ID: 20297641
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Patterns and costs associated with progression of age-related macular degeneration.
    Schmier JK, Covert DW, Lau EC.
    Am J Ophthalmol; 2012 Oct 12; 154(4):675-681.e1. PubMed ID: 22835513
    [Abstract] [Full Text] [Related]

  • 19. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.
    Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y.
    Ophthalmology; 2008 Jan 12; 115(1):141-6. PubMed ID: 17582498
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR, Moride Y, Rochon S.
    Clin Ther; 2007 Sep 12; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.